EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

The Efficacy and Safety of Albumin‐Bound Paclitaxel Combined With Anlotinib and PD ‐1/ L1 Inhibitors For Treating Patients With Extensive‐Stage Small Cell Lung Cancer and Brain Metastasis: A Retrospective Cohort Study

Xiaobing Li iD, De Wu, Yi Peng, Jing Tang, Yuebing Wu

Cancer Medicine · 2024

DOI: 10.1002/cam4.70449 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Cancer Medicine, 2024. Verfasst von Xiaobing Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Indoles, Small Cell Lung Carcinoma, Lung Neoplasms, Brain Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Hubei Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Extensive‐stage small cell lung cancer (ES‐SCLC) suffering from brain metastases (BM) has a poor prognosis and lacks effective treatment selection. In this study, we explored the efficacy and safety of combination treatment of albumin‐bound paclitaxel (nab‐ptx), anlotinib, and PD‐1/L1 inhibitors for such special population.

Methods

A total of 55 patients diagnosed with ES‐SCLC and BM were enrolled in this retrospective study. Patients received a combination therapy consisting of nab‐ptx, anlotinib, and PD‐1/L1 inhibitors. The primary endpoints included overall response rate (ORR), progression‐free survival (PFS), overall survival (OS), and adverse events (AEs).

Results

The results demonstrated promising efficacy of the combination therapy for such patients, with an ORR of 36.36%, median PFS and OS of 5.0 and 10.0 m, correspondingly. Subgroup analyses indicated that treatment efficacy closely correlated with patients' Ds‐GPA (Diagnosis‐specified Graded Prognosis Assessment) scores. Mechanistic studies revealed that this regimen likely operates by reducing immune suppression to activate immune function, thereby exerting synergistic anti‐tumor effects. The common AEs include decreased appetite, nausea, leukopenia, hypertension, proteinuria, hand‐foot syndrome, peripheral neuropathy, rash, and thyroid toxicity, most of which are generally mild and can be alleviated with symptomatic treatment.

Conclusion

The combination of nab‐ptx, anlotinib, and PD‐1/L1 inhibitors exhibited substantial efficacy and acceptable safety in the treatment of BM from ES‐SCLC. This novel therapeutic approach holds promise for improving the outcomes for patients with this challenging disease. Further studies are needed to validate these findings and investigate the long‐term benefits of this combination regimen.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IndolesSmall Cell Lung CarcinomaLung NeoplasmsBrain NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsQuinolinesAlbuminsPaclitaxelHumansMaleFemaleRetrospective StudiesMiddle AgedAgedImmune Checkpoint InhibitorsB7-H1 AntigenAdultNeoplasm StagingProgrammed Cell Death 1 ReceptorTreatment Outcome

Stichwörter der Autor:innen

PD‐1SCLCalbumin‐bound paclitaxelanlotinibbrain metastasis

Substanzen

anlotinibIndolesQuinolinesAlbuminsPaclitaxelImmune Checkpoint InhibitorsB7-H1 Antigen130-nm albumin-bound paclitaxelCD274 protein, humanProgrammed Cell Death 1 Receptor

Autor:innen und Institutionen

  • Department of Thoracic Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Department of Pathology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Department of Radiotherapy, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Department of Lymphoma, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

ORCID-Profile: Xiaobing Li

Förderung

  • Natural Science Foundation of Hubei Province

Zitieren

APA

Li, X., Wu, Peng, Y., Tang, J., & Wu, Y. (2024). The Efficacy and Safety of Albumin‐Bound Paclitaxel Combined With Anlotinib and PD ‐1/ L1 Inhibitors For Treating Patients With Extensive‐Stage Small Cell Lung Cancer and Brain Metastasis: A Retrospective Cohort Study. Cancer Medicine. https://doi.org/10.1002/cam4.70449

Vancouver

Li X, Wu, Peng Y, Tang J, Wu Y. The Efficacy and Safety of Albumin‐Bound Paclitaxel Combined With Anlotinib and PD ‐1/ L1 Inhibitors For Treating Patients With Extensive‐Stage Small Cell Lung Cancer and Brain Metastasis: A Retrospective Cohort Study. Cancer Medicine. 2024. doi:10.1002/cam4.70449

BibTeX
@article{Li2024,
  author = {Li, Xiaobing and Wu, De and Peng, Yi and Tang, Jing and Wu, Yuebing},
  title = {The Efficacy and Safety of Albumin‐Bound Paclitaxel Combined With Anlotinib and PD ‐1/ L1 Inhibitors For Treating Patients With Extensive‐Stage Small Cell Lung Cancer and Brain Metastasis: A Retrospective Cohort Study},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.70449}
}
Kostenlos starten →